Role of Gut Microbiota-derived Metabolites in the Pathogenesis and Progression of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Systematic Review.

```mdx

title: "Gut Microbiota Metabolites and MASLD: What a Systematic Review Tells Us"

description: "A PRISMA 2020 systematic review of 28 studies examines how gut-derived metabolites such as bile acids, ethanol, short-chain fatty acids, and indole derivatives relate to steatosis, steatohepatitis, fibrosis, and liver cancer."

date: "2026"

study_type: "Systematic review"

journal: "Journal of Gastrointestinal and Liver Diseases"

pubmed_id: "42927668"

TL;DR

A systematic review of 28 studies suggests that gut microbiota-derived metabolites, particularly conjugated bile acids and endogenous ethanol, may play a meaningful role in the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). The evidence is promising but largely observational and mechanistic, so it should be read as a hypothesis-generating body of work rather than established clinical guidance.

What the study found

Metabolic dysfunction-associated steatotic liver disease, formerly called non-alcoholic fatty liver disease, is closely linked to obesity, type 2 diabetes, and cardiovascular risk. Researchers have increasingly asked whether the gut microbiome, and the small molecules it produces, contributes to the disease process. This systematic review, registered in PROSPERO (CRD420261293786) and conducted under PRISMA 2020 guidelines, searched PubMed/Medline, Embase, Web of Science, and Scopus through December 2025. It included observational human studies, randomized trials, animal studies, and in vitro mechanistic work, then synthesized the findings narratively because the included data were too heterogeneous for meta-analysis.

Across the 28 included studies, changes in several classes of metabolites were associated with different stages of the disease. Alterations in bile acids, ethanol, fatty acids, and indole derivatives were linked to steatosis, steatohepatitis, fibrosis, and hepatocellular carcinoma (HCC). Bile acid profiles appeared to shift with disease stage, and endogenous ethanol was reported at generally elevated levels across studies. The authors noted that conjugated bile acids and endogenous ethanol were the most consistently highlighted candidates, though this consistency reflects the frequency with which they were studied rather than a formal comparison of effect sizes.

Short-chain fatty acids, produced when gut bacteria ferment dietary fiber, were found to have varied roles in MASLD pathogenesis rather than a single uniform effect. This is an important caveat: the same class of molecule can be protective in one context and contributory in another, depending on dose, location, and host factors. Indole derivatives, which are produced from dietary tryptophan by gut bacteria, were reported to attenuate hepatic steatosis and inflammation in the studies reviewed, largely in preclinical models. The authors also reported that altering the gut microbiota was associated with reduced progression of liver cancer, though this is an area where the supporting data are especially limited and largely derived from animal and mechanistic work.

The evidence base has clear limitations, and the authors acknowledged them. Much of the included work is animal or in vitro research, which cannot be directly translated to human physiology. Human studies were heterogeneous in design, sample handling, and metabolite measurement. Because no meta-analysis was performed, the review cannot estimate pooled effect sizes or confirm that any single metabolite causes disease. Where findings conflict across studies, the review does not resolve those conflicts. The conclusion that these metabolites are "highly promising" reflects the authors' interpretation of a mechanistically coherent but incompletely validated picture.

What this means for you

The most useful takeaway is conceptual: the gut and liver are in constant metabolic communication, and what the microbiome produces can influence liver fat, inflammation, and fibrosis in experimental settings. That framing may help explain why diet, body weight, and metabolic health are so closely tied to liver outcomes.

It would be premature to change clinical practice based on this review. No metabolite identified here has been validated as a treatment target or diagnostic marker for routine use, and the review itself calls for higher-quality human trials. Anyone with MASLD should work with a clinician on established approaches, which include weight management, glycemic control, and physical activity.

Some general habits that support metabolic health are well studied in their own right, though this review did not test them directly. Dietary fiber is the main dietary input for short-chain fatty acid production, so a high-fiber diet is a reasonable general strategy. Regular resistance training and Zone 2 cardio support insulin sensitivity and liver fat reduction in the broader literature. Reducing alcohol intake is particularly relevant given that ethanol was a focus of this review, and alcohol is an established liver stressor independent of the microbiome. Consuming fermented foods is sometimes suggested for gut health, but the evidence linking them specifically to MASLD outcomes is not established.

Supplements are not addressed by this review, and it should not be read as support for any product. Readers considering supplements for liver health should discuss them with a clinician first, particularly because some can interact with liver function.

Study details

Sources

1. Journal of Gastrointestinal and Liver Diseases. Role of Gut Microbiota-derived Metabolites in the Pathogenesis and Progression of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Systematic Review. PubMed. https://pubmed.ncbi.nlm.nih.gov/42927668/

```